Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 11
Submit an article Journal homepage
204
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Profound response to venetoclax monotherapy in a patient with BCL-2 positive relapsed multiple myeloma and extramedullary CNS manifestations

David M. Cordas dos Santosa Department of Medicine III, University Hospital, LMU Munich, Munich, Germany;b Cancer- and Immunometabolism Research Group, Gene Center LMU, Munich, Germany;c German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, GermanyORCID Iconhttps://orcid.org/0000-0002-9198-8338View further author information
ORCID Icon,
Tanja Pauld Institute of Pathology, LMU Munich, Munich, GermanyView further author information
,
Wolfgang G. Kunze Department of Radiology, University Hospital, LMU Munich, GermanyView further author information
,
Martina Rudeliusd Institute of Pathology, LMU Munich, Munich, GermanyView further author information
&
Sebastian Theuricha Department of Medicine III, University Hospital, LMU Munich, Munich, Germany;b Cancer- and Immunometabolism Research Group, Gene Center LMU, Munich, Germany;c German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, GermanyCorrespondence[email protected]
View further author information
Pages 2706-2710 | Received 04 Mar 2022, Accepted 24 Jun 2022, Published online: 06 Jul 2022

References

  • Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann oncol. 2010;21(2):325–330.
  • Fassas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002;117(1):103–108.
  • Nieuwenhuizen L, Biesma DH. Central nervous system myelomatosis: review of the literature. Eur J Haematol. 2008;80(1):1–9.
  • Muscal JA, Sun Y, Nuchtern JG, et al. Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemother Pharmacol. 2012;69(4):943–947.
  • Li Z, Qiu Y, Personett D, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013;8(8):e71754.
  • Vercruyssen M, El Hachem G, Maerevoet M. The Daratumumab crosses the blood brain barrier. Clin Lymphoma Myeloma Leuk. 2018;18:S289.
  • Jurczyszyn A, Grzasko N, Gozzetti A, et al. Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016;91(6):575–580.
  • Gangat N, Tefferi A. Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points. Blood Cancer J. 2020;10(11):122.
  • Kumar S, Harrison SJ, Cavo M, et al. Final overall survival results from BELLINI, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):84–84.
  • Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t (11; 14) multiple myeloma. Blood J Am Soc Hematol. 2017;130(22):2401–2409.
  • Harrison S, Cavo M, De la Rubia J, et al. T (11; 14) and high BCL2 expression are predictive biomarkers of response to venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: biomarker analyses from the phase 3 Bellini study. Washington, DC; American Society of Hematology; 2019.
  • Reda G, Cassin R, Dovrtelova G, et al. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. Haematologica. 2019;104(5):e222–e223.
  • Salem AH, Badawi MA, Place AE, et al. Venetoclax Crosses the blood brain barrier: a pharmacokinetic analysis of the cerebrospinal fluid in pediatric leukemia patients. Blood. 2020;136(Supplement 1):30–31.
  • Egan PA, Elder PT, Deighan WI, et al. Multiple myeloma with central nervous system relapse. Haematologica. 2020;105(7):1780–1790.
  • Anderson KC. editor Lenalidomide and thalidomide: mechanisms of action—similarities and differences. Seminars in Hematology. 2005;42:S3–S8.
  • Bobillo S, Abrisqueta P, Carpio C, et al. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement. Haematologica. 2018;103(2):e92–e3.
  • Claudel A, Talbot A, Harel S, et al. Thiotepa intrathecal injections for myelomatous central nervous system involvement. Br J Haematol. 2021;193(2):e9–e12.
  • Tsuyama N, Sakata S, Baba S, et al. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood J Am Soc Hematol. 2017;130(4):489–500.
  • Kapoor I, Bodo J, Hill BT, et al. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis. 2020;11(11):941.
  • Bazarbachi AH, Avet-Loiseau H, Szalat R, et al. IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood. 2021;138(20):1980–1985.
  • Condorelli A, Matteo C, Leotta S, et al. Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement. Cancer Chemother Pharmacol. 2022;89(2):267–270.
  • Matulis SM, Gupta VA, Neri P, et al. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. Leukemia. 2019;33(5):1291–1296.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.